Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 16
Tirzepatide anhedonia: three case reports
Three patients reported improved motivation after tirzepatide dose reduction, but the uncontrolled case series cannot establish frequency or causation.
GLP-1 drugs in dermatologic disease
A 2026 review links GLP-1 drugs with inflammatory skin disease, but its clearest clinical evidence comes from one psoriatic arthritis trial.
GLP-1 drugs and diabetic foot reports
A 2026 FAERS analysis found a lower proportional reporting signal for diabetic foot complications, but it did not measure patient incidence or prove protection.
MASH fibrosis treatment panel update
An expert panel maps how semaglutide and resmetirom may fit MASH care, while long-term outcomes and direct comparisons remain open.
Retatrutide access opens case by case
A US registry now lists individual-patient retatrutide expanded access as available under narrow criteria. It is not approval or broad availability.
Semaglutide plus exercise in rats
A four-week rat study found partly distinct metabolic effects from semaglutide and aerobic training, with no direct evidence for menopausal women.
Semaglutide neuropathy case report
A single case found improved corneal nerve measurements after semaglutide, while neuropathy symptoms and disability scores stayed unchanged.
Semaglutide carbon model: what it found
A UK model estimated slightly lower lifetime emissions in two obesity populations but higher emissions with established cardiovascular disease.
TB-500 in Sweden: import rules explained
TB-500 has no Swedish or EMA marketing authorisation and has been on the WADA Prohibited List since 2018. Here is what that means under Swedish law.
Tesamorelin cost in the Netherlands
Tesamorelin has no EMA authorisation after the 2012 withdrawal. No GVS listing, no official Dutch price, no ZVW cover exists. Here is the full picture for 2026.
Tirzepatide: what experts said, Q2 2026
SURMOUNT-MAINTAIN, a safety review on sarcopenia risk, and early type-1 diabetes signals from credentialed researchers this quarter.
GLP-1 Drugs and Anesthesia Safety
A 2026 study compared anesthesia outcomes for lipoabdominoplasty patients taking semaglutide or tirzepatide against those who were not.